Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
Complete Title: A Phase Ib open label study to assess the safety and pharmacokinetics of
NUC-3373, a nucleotide analogue, given in combination with standard
agents used in colorectal cancer treatment
Trial Phase: I/II
Investigator: Andrew Coveler, MD
This is a two-part study of NUC-3373 administered every 2 weeks as an intravenous infusion, in separate combinations with leucovorin, oxaliplatin, oxaliplatin + bevacizumab, oxaliplatin + panitumumab, irinotecan, and irinotecan + cetuximab. The primary objective is to identify a recommended dose for NUC-3373 when combined with these agents.
Keywords:
- Colorectal Neoplasms
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Andrew Coveler, MD
RG1003420
NCT03428958
A Phase Ib open label study to assess the safety and pharmacokinetics of
NUC-3373, a nucleotide analogue, given in combination with standard
agents used in colorectal cancer treatment
Colorectal Neoplasms